12th International Congress on Myeloproliferative Neoplasms


 

Moving Beyond JAKi: Ruxolitinib Failure, Newly Approved and in Development JAKi, & Novel Therapies (JAKi Combo & Novel Agents)

114 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login